Effects of intrastriatal administration of selective dopaminergic ligands on spontaneous stereotypy in mice.
Abnormal repetitive behaviors are often associated with specific developmental, genetic, and neuropsychiatric disorders. Repetitive motor behaviors, often referred to as stereotypies, have been studied extensively as they can be readily induced by certain drugs (e.g., amphetamine). Recent work has shown, however, that such drug-induced models of stereotypy may not accurately reflect the neurobiological perturbations responsible for the spontaneous manifestation of these behaviors. The present study employed the deer mouse model of spontaneous and persistent stereotypy to evaluate the capacity of several selective dopaminergic agonists (apomorphine, SKF81297, and quinpirole) to exacerbate levels of spontaneously emitted stereotypic topographies when administered intrastriatally. Additionally, the effects of intrastriatal administration of the D(2)R antagonist raclopride on the expression of spontaneous stereotypic jumping were evaluated. No induction or exacerbation of stereotypy was observed following administration of the selective D(1)- or D(2)- receptor agonists, and the mixed agonist apomorphine induced hyperlocomotion and excessive grooming but failed to exacerbate spontaneous stereotypy. Thus, a dissociation was observed between spontaneously emitted and drug-induced stereotypy, suggesting significant limitations to the use of dopamine agonist-induced stereotypy as a model of clinical stereotyped movement disorder. Furthermore, an unexpected and statistically significant (P<.05) potentiation of locomotor activity was observed following intrastriatal raclopride administration, suggesting major alterations to the modulatory characteristics of the striatal dopaminergic system in these spontaneously stereotypic animals.
Presti
Michael F
MF
Department of Neuroscience, University of Florida, 100 S. Newell Drive, P.O. Box 100256, Gainesville, FL 32610-0256, USA.
Gibney
Barry C
BC
Lewis
Mark H
MH
D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage; D001552:Benzazepines / Q000008:administration & dosage; D018491:Dopamine Agonists / Q000008:administration & dosage*; D018492:Dopamine Antagonists / Q000008:administration & dosage; D005260:Female; D007267:Injections; D008124:Locomotion / Q000187:drug effects; D008297:Male; D017072:Neostriatum / Q000187:drug effects* / Q000378:metabolism; D010542:Peromyscus; D019257:Quinpirole / Q000008:administration & dosage; D020891:Raclopride / Q000008:administration & dosage; D011954:Receptors, Dopamine / Q000187:drug effects*; D013239:Stereotyped Behavior / Q000187:drug effects*
D001552:Benzazepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D019257:Quinpirole; D020891:Raclopride; C067113:SK&F 81297; D001058:Apomorphine